Clinical trials: Kidney Glomerulus
IgA Nephropathy, Immunoglobulin A Nephropathy
Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy
The ASSIST study was a phase 2, double-blind, placebo-controlled crossover study to evaluate the safety and efficacy of atrasentan vs.
- Trial name
- ASSIST (NCT05834738)
- Testing
- Atrasentan
- Where
- 30 sites in United States, Australia and 4 more
- Volunteers
- 54 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Transplantation
Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Kidney Transplant Recipients
This study will investigate the safety, tolerability and efficacy of EC-MPS with tacrolimus at both reference and reduced levels.
- Trial name
- NCT00229138
- Testing
- EC-MPS, Tacrolimus
- Where
- United States
- Volunteers
- 291 people
- Sponsor
- Novartis Pharmaceuticals
Acute Kidney Injury
Tolerability and Background Fluorescence of the MediBeacon Transdermal GFR Measurement System
This study is designed to evaluate background fluorescence of participants of different ages, gender, and skin color. In addition, 48-hour tolerability of the sensor and adhesive will be evaluated.
- Trial name
- NCT03810833
- Testing
- Brilliance device sensor
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- MediBeacon
Type 2 Diabetics, Chronic Kidney Disease, Protein in Urine
A Study to Evaluate the Safety and Tolerability of ABT-614 and Its Effect on Kidney Function in Subjects With Type 2 Diabetes and Chronic Kidney Disease With Protein in Their Urine.
To assess the safety, tolerability and pharmacokinetics of ABT-614 in subjects with type 2 diabetes and chronic kidney disease with albuminuria and to determine whether ABT-614 reduces glomerular filtration rate.
- Trial name
- NCT01464320
- Testing
- ABT-614
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Abbott
Renal Impairment
A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment
The objective of this study is to assess and compare the pharmacokinetic properties of YM178 in normal subjects and those with mild, moderate and severe renal impairment.
- Trial name
- NCT00750620
- Testing
- YM178
- Where
- 2 sites in United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Chronic Renal Insufficiency, Diabete Mellitus
Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Procedure
To evaluate cardio-renal and overall safety profile of GE 145 320 mg I/ml Injection when compared to iopamidol 370 mg I/mL. The study will focus on elderly subjects with either chronic renal insufficiency, or diabetes mellitus…
- Conditions
- Chronic Renal Insufficiency, Diabete Mellitus, Congestive Heart Failure
- Trial name
- NCT01252810
- Testing
- GE-145
- Where
- United States
- Volunteers
- 284 people
- Sponsor
- GE Healthcare
Anti-Glomerular Basement Membrane Disease
A Clinical Trial With KJ103 in Anti-GBM Disease
An open-label, single-arm Phase II study to evaluate the preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and immunogenicity of KJ103 in patients with anti-GBM disease.
- Trial name
- NCT06607016
- Testing
- KJ103 for Injection, Cyclophosphamide, Glucocorticoids
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Shanghai Bao Pharmaceuticals Co., Ltd.
Immunoglobulin A Nephropathy, Glomerular Disease
Safety and Efficacy Study of VIS649 for IgA Nephropathy
The purpose of this study is to evaluate the efficacy and safety of VIS649 in participants with immunoglobulin A (IgA) Nephropathy (IgAN)
- Conditions
- Immunoglobulin A Nephropathy, Glomerular Disease, IgAN
- Trial name
- NCT04287985
- Testing
- Low Dose-VIS649, Medium Dose-VIS649, High Dose-VIS649
- Where
- 93 sites in United States, Australia and 13 more
- Volunteers
- 155 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Healthy
A Comparison of the Effects of Extended Release Tacrolimus (Advagraf®) vs. Immediate Release Tacrolimus (Prograf®) on Kidney Function in Healthy Male Volunteers
The purpose of the study is to evaluate the drug profiles (pharmacokinetics) and effects (pharmacodynamics) of Advagraf® and Prograf® on the kidneys.
- Trial name
- NCT01681134
- Testing
- Advagraf®, Prograf®
- Where
- Canada
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Canada, Inc.
Kidney Diseases, Glomerulosclerosis
An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases
This is an open-label Phase 2 study evaluating the long term safety and tolerability of GFB-887 in patients with focal segmental glomerulosclerosis (FSGS), and treatment-resistant minimal change disease (TR-MCD)
- Conditions
- Kidney Diseases, Glomerulosclerosis, Focal Segmental Nephrosis, Lipoid Urologic Disease
- Trial name
- NCT04950114
- Testing
- GFB-887
- Where
- 17 sites in United States
- Volunteers
- 31 people
- Sponsor
- Goldfinch Bio, Inc.
Chronic Kidney Disease
A Study to Examine Past Estimated Glomerular Filtration Rate (eGFR) Slope as a Risk Marker for Rapid Kidney Function Decline in People With Chronic Kidney Disease
This study is intended to investigate the usefulness of estimated glomerular filtration rate (eGFR) slopes derived from retrospective routine clinical practice data, compare those retrospective slopes with those generated in a…
- Trial name
- NCT04881448
- Testing
- collection of serum/capillary creatinine values
- Where
- 25 sites in United States, Germany and 2 more
- Volunteers
- 223 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes
The purpose of this study is to evaluate the effects of dapagliflozin on kidney function, as assessed by glomerular filtration rate.
- Trial name
- NCT00976495
- Testing
- Dapagliflozin, Hydrochlorothiazide
- Where
- 12 sites in United States, Canada and 1 more
- Volunteers
- 154 people
- Sponsor
- AstraZeneca
Kidney Diseases, Kidney Injury
Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring
The goal of this clinical trial was to compare transdermal glomerular filtration rate (tGFR) to plasma-derived indexed GFR (nGFR) using MB-102 (relmapirazin) as the fluorescent compound.
- Conditions
- Kidney Diseases, Kidney Injury, Kidney Failure
- Trial name
- NCT05777174
- Testing
- MB-102, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)
- Where
- 5 sites in United States
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- MediBeacon
Renal Function
Study to Develop a Tool to Estimate the Kidney Function in Databases Without Laboratory Data
Scientific analyses are frequently performed on e.g. health insurance databases to study the usage and effectiveness of drugs in real life.
- Trial name
- NCT03605810
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 5,132,200 people
- Sponsor
- Bayer
Glomerular Disease, Proteinuria
Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease
The major objective is to demonstrate the safety and efficacy of ANG-3070 in patients with primary glomerular disease and persistent proteinuria.
- Trial name
- NCT04939116
- Testing
- ANG-3070
- Where
- 30 sites in United States, Australia and 1 more
- Volunteers
- 100 people
- Sponsor
- Angion Biomedica Corp